HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Schenk, P. Articles by Lang, I. Search for Related Content PubMed PubMed Citation Articles by Schenk, P. Articles by Lang, I.

Aerosolized Iloprost Therapy Could Not Replace Long-term IV Epoprostenol (Prostacyclin) Administration in Severe Pulmonary Hypertension*

Objectives: To switch patients with severe pulmonary hypertension and previous life-threatening catheter-related complications from long-term IV epoprostenol therapy to aerosolized iloprost therapy.

Design: Open, uncontrolled trial.

Setting: Medical ICU of a university hospital.

Patients: Two patients with primary pulmonary hypertension and one patient with pulmonary hypertension after surgical closure of atrial septal defect (mean pulmonary artery pressure 50 mm Hg). All were classified as New York Heart Association class II under treatment with continuous IV epoprostenol for 4 years.

Interventions: Stepwise reduction of IV epoprostenol (1 ng/kg/min steps every 3 to 10 h) during repeated inhalations of aerosolized iloprost (150 to 300 µg/d with 6 to 18 inhalations/d). Continuous pulmonary and systemic arterial monitoring were performed.

Results: Aerosolized iloprost reduced pulmonary artery pressure by 49%, 49%, and 45%, respectively, and increased cardiac output by 70%, 75%, and 41% in the three patients. The effect lasted for 20 min and was similar at different doses of IV epoprostenol. Persistent treatment change to inhaled iloprost could not be achieved because all patients developed signs of right heart failure. After termination of iloprost inhalations, return to standard epoprostenol therapy led to clinical and hemodynamic restoration.

Conclusions: Although aerosolized iloprost demonstrated short-term hemodynamic effects, it could not be utilized as alternative chronic vasodilator in patients with severe pulmonary hypertension.

Key Words: aerosolized iloprost • catheter-related complications • inhaled vasodilator therapy • pulmonary hypertension

This article has been cited by other articles:

				S. E Baker and R. H. Hockman Inhaled Iloprost in Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274. [Abstract] [Full Text] [PDF]

				T. Kramm, B. Eberle, F. Krummenauer, S. Guth, H. Oelert, and E. Mayer Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy Ann. Thorac. Surg., September 1, 2003; 76(3): 711 - 718. [Abstract] [Full Text] [PDF]

				F. M. Fruhwald, B. Kjellstrom, W. Perthold, N. Watzinger, R. Maier, P. A. Grandjean, and W. Klein Continuous Hemodynamic Monitoring in Pulmonary Hypertensive Patients Treated With Inhaled Iloprost Chest, July 1, 2003; 124(1): 351 - 359. [Abstract] [Full Text] [PDF]

				K. Chatterjee, T. De Marco, and J. S. Alpert Pulmonary Hypertension: Hemodynamic Diagnosis and Management Arch Intern Med, September 23, 2002; 162(17): 1925 - 1933. [Abstract] [Full Text] [PDF]